Enliven Therapeutics CMO sells $250,000 in shares

Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics, exercised options for 5,000 shares at $2.48 on Sept. 17, 2026. She subsequently sold 5,000 shares at weighted average prices of $50.03, $50.71, and $51.48. Her beneficial ownership in common stock is now 25,000 shares. Collins still holds 106,268 stock options.